TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00571402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-focused therapy for adolescents
Description: FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced care
Description: Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
Study: NCT00040846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT03406676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
Study: NCT04695678

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 nasal/pharyngeal swab
Description: each study participant receives a nasal/pharyngeal swab

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 nasal/pharyngeal swab
Description: each study participant receives a nasal/pharyngeal swab
Study: NCT00153842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene (targretin)
Description: Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene (targretin)
Description: Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg
Study: NCT01756755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMX-20R Hemoperfusion
Description: Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
Study: NCT01805050

Intervention type: PROCEDURE
Intervention: Arthroscopically repair of the anterior shoulder instability
Description: Arthroscopically repair of the anterior shoulder instability
Study: NCT00040846

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic HSCT
Study: NCT03740490

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Smart-T + NRT
Description: Smart-Treatment App and Nicotine Replacement Therapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide + NRT
Description: NCI QuitGuide Treatment App and Nicotine Replacement Therapy
Study: NCT00040846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study: NCT02691572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine
Description: Bupivacaine 12.5 mg will be administered in the subarachnoid space.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal bupivacaine
Description: Bupivacaine 12.5 mg will be administered in the subarachnoid space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Description: Fentanyl 15 µg will be administered in the subarachnoid space.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal fentanyl
Description: Fentanyl 15 µg will be administered in the subarachnoid space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Description: Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean delivery
Description: Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients' abdomen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: IV ketorolac 30 mg/8 h starting at the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IV ketorolac 30 mg/8 h starting at the end of surgery.
Study: NCT03742440

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GrafixPL PRIME
Description: GrafixPL PRIME
Study: NCT00998777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder Strengthening
Description: The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
Study: NCT04745273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG (Kemoset 4mg)
Description: Ondansetron 4mg (iv) will administer to participants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Salin solution
Description: Salin solution 2ml (iv) will administer to participants
Study: NCT05023824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-blocker or 5-ARI withdrawal
Description: Withdrawal of either alpha-blocker or 5-ARI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-blocker or 5-ARI withdrawal
Description: Withdrawal of either alpha-blocker or 5-ARI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of alpha-blocker and 5-ARI
Description: Maintenance of alpha-blocker and 5-ARI
Study: NCT02003274

Intervention type: OTHER
Group type: OTHER
Intervention: Clamp-Mixed Meal
Description: Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal.

Intervention type: OTHER
Group type: OTHER
Intervention: IVGTT-Mixed Meal Arm
Description: Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal.
Study: NCT01931709

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01028690

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00040456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mg Pidolate
Description: Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
Study: NCT01640327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine (TIVf)
Description: A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
Study: NCT01569243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messages
Description: * Participants will receive diabetic medical care as usual.~* Participants will be given an ActiHealth pedometer to measure daily activity.~* In addition, they will be enrolled to receive the study text messages.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: * Participants will receive diabetic medical care as usual.~* In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity).
Study: NCT04074239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video triage
Description: The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
Study: NCT01792570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV + DRV/r
Description: Switch to dual HAART

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continue the PI/r-containing HAART.
Description: Continue the on-going triple drug HAART.
Study: NCT03740815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus plane block
Description: Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Description: Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous sedation
Description: Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
Study: NCT03256890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-BP Intervention
Description: MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control
Description: Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance.
Study: NCT01107379

Intervention type: DEVICE
Intervention: Relieva Balloon Sinuplasty System
Description: Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
Study: NCT03655002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02691572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Oral paracetamol 1 gm/8 h starting 4 h after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Oral paracetamol 1 gm/8 h starting 4 h after surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fentanyl patient-controlled analgesia
Description: Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
Study: NCT02256722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL
Study: NCT02691572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl patient-controlled analgesia
Description: Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
Study: NCT02256722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Study: NCT01900340

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous saline infusion and intraduodenal administration of saline via feeding tube

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin 9-39
Description: IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
Study: NCT02715557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention program
Description: The relapse prevention program is an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse prevention program
Description: The relapse prevention program is an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
Study: NCT01555931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system
Description: Placement within 48 hours of delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Description: Placement within 48 hours of delivery
Study: NCT06250114

Intervention type: OTHER
Intervention: Retreatment
Description: manual k file, carrier based technique, Xrays, tooth build up, provisional and definitive crowns. Post if necessary will be placed

Intervention type: OTHER
Intervention: extraction implant
Description: Flapless or flapped techniques, early, delayed and immediate implant insertions. Cement retrained restorations
Study: NCT04604860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness intervention
Description: Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).
Study: NCT01510756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
Study: NCT05758454

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caries and Obesity Prevention
Description: A culturally adapted oral health education intervention to prevent development of ECC and to improve parental oral health related knowledge and attitudes.
Study: NCT00805532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation treatment
Description: Behavioral Activation (BA) is a present-focused psychotherapy based on behavioral theory and principles of change, that aims to re-engage individuals with meaningful and pleasurable life activities by targeting and problem-solving patterns of avoidance. It is well-established as a treatment for depression and has been modified for the current study to address PTSD-related problems.
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study: NCT03083717

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)
Description: 2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)
Description: 2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
Study: NCT00805532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
Study: NCT02813460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study: NCT00759772

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: 20 mcg sc daily for 6 months
Study: NCT04241575

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simple fibrosis scores and electronic reminder messages
Description: For patients in the intervention group, we will calculate the fibrosis scores. For patients with increased fibrosis scores, we will type the following pop-up message in our electronic clinical management system:~This patient has high Fibrosis-4 index (and/or AST-to-platelet ratio index) of xxx suggestive of significant liver fibrosis. Please consider referring the patient to the hepatology clinic or arranging further test such as FibroScan.~The reminder message will pop up when physicians see the patient at the clinic and use the electronic clinical management system. The message will remain active for one year. Although the message is entered manually at this stage, the arrangement mimics an automated computer system. If the study results are positive, the next step is to modify the system to automate the process.
Study: NCT02978313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: anti-EGFR monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: anti-EGFR monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Oxaliplatin+LV5FU2